One provision of the Lower Health Care Costs Act that has garnered significantly less attention from the broader healthcare community has raised concerns among many biologics stakeholders.
USP in the News
Center for Biosimilars
Little-Known Provision of Senate Healthcare Bill Has Some Biosimilar Stakeholders Worried
Inside Health Policy
Experts: Biologic Product Monographs Do Not Impede On FDA’s Authority
Some biologics experts are perplexed by the Trump administration’s argument that subjecting biologics products to United States Pharmacopeia (USP) monographs would hamper innovation.
News Releases & Announcements
Quality Matters Blog
Our legacy of championing access to medicines
Ron Piervincenzi, Ph.D., shares his thoughts on USP receiving the Association of Accessible Medicines (AAM) Champion of Access award.
USP volunteers help shape the future of drug manufacturing
Consistent quality. Greater access. They’re what patients deserve and what USP strives to ensure across the globe through the development of public quality standards.
Medicine quality must be assured, not assumed
Poor-quality medicines receives little attention in public health policy discussions, yet is a worldwide problem.
New Brand Identity
USP’s new brand identity reflects who USP is today and the dynamic future ahead.
We took this step because we wanted to better communicate how we work with partners to build and reinforce a foundation that draws us closer to a world where everyone can be confident of quality in health and healthcare.
Stay Connected…
Sign up for the latest USP News Releases!